Healthcare
Larimar Therapeutics, Inc.(LRMR)
Live Price
Offline$3.72
+5.08% today
1Y Change
+8.92%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $340.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -72.0%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Larimar Therapeutics, Inc. (LRMR) is a Healthcare stock with a market cap of $340.00M and listed on NASDAQ. The stock last traded around $3.72 and up 8.9% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -72.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -72.0%, free cash flow -59.0% with operating margin 0.0% and ROIC -210.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines LRMR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -72.0%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.9% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | -6.5% | -4.4% | -19.6% |
2026 Mar 19, 2026 | -65.9% | +0.4% | +8.5% | +7.4% |
2025 Nov 5, 2025 | -56.4% | +7.8% | +4.7% | +14.3% |
Benchmark Edge
LRMR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LRMR
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LRMR Max Drawdown
-47.90%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LRMR and SPY.
Company Overview
Larimar Therapeutics, Inc.
NASDAQ Global Market
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
- Leadership
- Carole S. Ben-Maimon
- IPO Date
- Jun 19, 2014
- Employees
- 65
- Street Address
- Three Bala Plaza East
- Mailing
- Bala Cynwyd, PA, 19004
- Region
- Bala Cynwyd, PA, US
- Reporting Currency
- USD
- Investor Line
- 844 511 9056
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 4.3
Growth
- Revenue
- 0.0%
- EPS
- -72.0%
- Free Cash Flow
- -59.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -137.7%
- ROIC
- -210.0%
Balance Sheet
- Debt/Equity
- 0.05
- Current Ratio
- 2.19
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.